Complete Bibliography

Visit PubMed to view Dr. Andy McGuire's complete publication record.

Selected Publications

Targeting RSV-neutralizing B cell receptors with anti-idiotypic antibodies. Scharffenberger, S.C., Wan, Y-H., Homad, L.J., Kher, G., Haynes, A.M., Poudel, B., Sinha, I., Aldridge, N., Pai, A., Bibby, M., Chhan C., Moodie, Z., Palacio, M.B., Escolano, A., McElrath, M.J., Boonyaratanakornkit, J., Pancera, M., and McGuire, A.T. Cell Rep. Oct 22;43(10):114811, 2024. 

A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge. Edwards KR, Malhi H, Schmidt K, Davis AR, Homad LJ, Warner NL, Chhan CB, Scharffenberger SC, Gaffney K, Hinkley T, Potchen NB, Wang JY, Price J, McElrath MJ, Olson J, King NP, Lund JM, Moodie Z, Erasmus JH, McGuire AT. NPJ Vaccines. 2024 Jun 26;9(1):120. doi: 10.1038/s41541-024-00907-y.

Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus. Edwards KR, Schmidt K, Homad LJ, Kher GM, Xu G, Rodrigues KA, Ben-Akiva E, Abbott J, Prlic M, Newell EW, De Rosa SC, Irvine DJ, Pancera M, McGuire AT. Cell Rep Med. 2024 Jun 18;5(6):101587. doi: 10.1016/j.xcrm.2024.101587.

Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge Malhi H, Homad LH, Wan YH, Poudel B, Fiala B, Borst AJ, Wang JY, Walkey C, Price J, Wall A, Singh S, Moodie Z, Handa S, Correnti C, Stoddard L, Veesler D, Pancera M, Olson J, Ning NP, McGuire AT. Cell Rep Med. Jun 21;3(6):100658. doi: 10.1016/j.xcrm.2022.100658.

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit Hurlburt NK, Homad LJ, Sinha I, Jennewein MF, MacCamy AJ, Wan YH, Boonyaratanakornkit J, Sholukh AM, Jackson AM, Zhou P, Burton DR, Andrabi R, Ozorowski G, Ward AB, Stamatatos L, Pancera M, McGuire AT. Commun Biol. 2022 Apr 11;5(1):342. doi: 10.1038/s42003-022-03262-7.

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection Stamatatos L, Czartoski J, Wan Y-H, Homad LJ,  Rubin V,  Glantz H, Neradilek M, Seydoux E, Jennewein MF, MacCamy AJ, Feng J, Mize G, De Rosa SC, Finzi A, Lemos M, Cohen KW, Moodie Z, McElrath MJ, McGuire AT. Science. 2021, (372) 6549, pp. 1413-1418

Structural basis for broad coronavirus neutralization. Sauer MM, Tortorici MA, Park YJ, Walls AC, Homad L, Acton OJ, Bowen JE, Wang C, Xiong X, de van der Schueren W, Quispe J, Hoffstrom BG, Bosch BJ, McGuire AT, Veesler D. Nat Struct Mol Biol. 2021 Jun;28(6):478-486

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies  Seydoux E, Wan  Y-H,  Feng J, Wall A, Aljedani S,Homad LJ,  MacCamy, AJ,  Weidle C, Gray MD,  Brumage L, Taylor J, Pancera M, Stamatatos L, McGuire AT.  Cell Reports. 2021 2021 May 4;35(5):109084

Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus Singh S, Homad LJ, Akins NR, Stoffers CM, Lackhar S, Malhi H, Wan Y-H, Rawlings DJ, McGuire AT. Cell Reports Medicine. 2020 1(3),100033 

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation Seydoux S,  Homad LJ,  MacCamy AJ,  Parks KR, , Hurlburt NK, Jennewein MF,  Akins NR, Stuart AB, Wan Y-H, Feng J, Whaley RE, Singh S, Boeckh M, Cohen KW, McElrath MJ, Englund JA, Chu HY, Pancera M, McGuire AT, Stamatatos, L. Immunity. Immunity. 2020 Jul 14;53(1):98-105.e5

Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses. Dosenovic P, Pettersson AK, Wall A, Thientosapol ES, Feng J, Weidle C, Bhullar K, Kara EE, Hartweger H, Pai JA, Gray MD, Parks KR, Taylor JJ, Pancera M, Stamatatos L, Nussenzweig MC, McGuire AT. J Exp Med. 2019 Jul 25. pii: jem.20190446. doi: 10.1084/jem.20190446. PMID: 31345931

Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. Bancroft T, DeBuysscher BL, Weidle C, Schwartz A, Wall A, Gray MD, Feng J, Steach HR, Fitzpatrick KS, Gewe MM, Skog PD, Doyle-Cooper C, Ota T, Strong RK, Nemazee D, Pancera M, Stamatatos L, McGuire AT, Taylor JJ. J Exp Med. 2019 Jul 25. pii: jem.20190164. doi: 10.1084/jem.20190164. PMID: 31345930

An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. Snijder J, Ortego MS, Weidle C, Stuart AB, Gray MD, McElrath MJ, Pancera M, Veesler D, McGuire AT. Immunity. 2018 Apr 17;48(4):799-811.e9. doi: 10.1016/j.immuni.2018.03.026. PMID: 29669253

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB, Glenn J, Seaman MS, Schief WR, Strong RK, Nussenzweig MC, Stamatatos L. Nat Commun. 2016 Feb 24;7:10618. doi: 10.1038/ncomms10618. PMID: 26907590

HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, Mouquet H, Stamatatos L. Science. 2014 Dec 12;346(6215):1380-1383. doi: 10.1126/science.1259206. PMID: 25504724

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L. J Exp Med. 2013 Apr 8;210(4):655-63. doi: 10.1084/jem.20122824. Epub 2013 Mar 25. PMID: 23530120